• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Aerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    4/29/25 4:05:20 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTE alert in real time by email
    8-K
    NASDAQ 0001798749 false 0001798749 2025-04-29 2025-04-29
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 29, 2025

     

     

    Aerovate Therapeutics, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Nevada   001-40544   83-1377888
    (State or other jurisdiction
    of incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    221 Crescent St., Building 23

    Suite 105
    Waltham, MA

      02453
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (781) 312-3013

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.0001 par value per share   JBIO   The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     

     
     


    Item 7.01

    Regulation FD Disclosure.

    On April 29, 2025, Jade Biosciences, Inc. (formerly known as Aerovate Therapeutics, Inc., the “Company”) made available an updated corporate presentation on the Company’s website.

    A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

    EXHIBIT INDEX

     

    Exhibit

    No.

       Description
    99.1    Corporate Presentation, dated April 2025
    104    Cover page interactive data file (embedded within the inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Aerovate Therapeutics, Inc.
        (Registrant)
    Date: April 29, 2025     By:  

    /s/ Tom Frohlich

        Name:   Tom Frohlich
        Title:   Chief Executive Officer
    Get the next $AVTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTE

    DatePrice TargetRatingAnalyst
    6/18/2024$27.00 → $2.00Outperform → In-line
    Evercore ISI
    6/18/2024Buy → Hold
    TD Cowen
    6/18/2024$35.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    6/17/2024Buy → Neutral
    Guggenheim
    6/17/2024Buy → Neutral
    BTIG Research
    6/17/2024$41.00 → $3.00Outperform → Neutral
    Wedbush
    3/25/2024$21.00 → $65.00Buy
    Jefferies
    12/8/2023$35.00Equal Weight
    Wells Fargo
    More analyst ratings

    $AVTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

      —Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi

      4/21/25 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of

      4/9/25 4:05:00 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. This expected dividend range is based on Aerovate's estimated net cash immediately prior to the closing of the Merger (the "Closing"). As of April 4, 2025, 28,985,019 shares of Aerovate's common stock are outstanding. Official declaration of the Cash D

      4/7/25 8:30:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Leadership Updates

    Live Leadership Updates

    See more
    • Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

      WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board. "We are pleased to have Habib take on the role of Chair of the Board," said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics. "With the Phase 2b data readout from our global IMPAHCT trial of AV-101 in PAH coming in June and our Phase 3 trial already well underway,

      3/6/24 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

      WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Habib Dable as a member of Aerovate's Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma Inc. and brings nearly three decades of experience working with emerging biotech and big pharma companies. "We are excited to welcome Habib to Aerovate's Board of Directors. Habib's deep experience in leading both big pharma and emerging biotech companies will be incredibly

      7/11/23 5:00:00 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

      WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate's Board of Directors. With over 40 years of working in the industry, Mr. Santel brings to Aerovate extensive experience in building successful pharmaceutical companies. "We are excited to welcome Don to Aerovate's Board of Directors. Don's proven track record of leading and building biopharmaceutical companies from the ground up and taking them through extensive periods of g

      1/23/23 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Financials

    Live finance-specific insights

    See more
    • Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

      —Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi

      4/21/25 8:00:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of

      4/9/25 4:05:00 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

      Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate. This expected dividend range is based on Aerovate's estimated net cash immediately prior to the closing of the Merger (the "Closing"). As of April 4, 2025, 28,985,019 shares of Aerovate's common stock are outstanding. Official declaration of the Cash D

      4/7/25 8:30:00 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aerovate Therapeutics downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Aerovate Therapeutics from Outperform to In-line and set a new price target of $2.00 from $27.00 previously

      6/18/24 7:32:31 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics downgraded by TD Cowen

      TD Cowen downgraded Aerovate Therapeutics from Buy to Hold

      6/18/24 7:23:55 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Aerovate Therapeutics from Overweight to Equal Weight and set a new price target of $2.00 from $35.00 previously

      6/18/24 7:22:03 AM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    SEC Filings

    See more
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Material Modification to Rights of Security Holders, Regulation FD Disclosure

      8-K - Jade Biosciences, Inc. (0001798749) (Filer)

      5/1/25 4:22:23 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Aerovate Therapeutics Inc.

      SCHEDULE 13D/A - Jade Biosciences, Inc. (0001798749) (Subject)

      4/30/25 4:51:40 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)

      4/29/25 4:05:20 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aerovate Therapeutics Inc.

      SC 13G/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      11/14/24 4:21:04 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aerovate Therapeutics Inc.

      SC 13D/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      6/20/24 6:00:09 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Aerovate Therapeutics Inc. (Amendment)

      SC 13D/A - Aerovate Therapeutics, Inc. (0001798749) (Subject)

      4/30/24 4:16:13 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fairmount Funds Management Llc

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:16:57 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lavelle Erin

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:15:30 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Klein Lawrence Otto

      4 - Jade Biosciences, Inc. (0001798749) (Issuer)

      5/1/25 6:10:20 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $1,549,944 worth of shares (928,110 units at $1.67) (SEC Form 4)

      4 - Aerovate Therapeutics, Inc. (0001798749) (Issuer)

      6/20/24 5:56:07 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTE
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

      Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

      6/21/24 3:23:59 PM ET
      $AVTE
      Biotechnology: Pharmaceutical Preparations
      Health Care